Found (511) clinical trials

You are being asked to take part in this study because you have a type of brain tumor called a glioblastoma multiforme (GBM) and you have completed the first part of your treatment with radiation combined with the chemotherapy drug temozolomide (TMZ). The standard treatment after completing radiation is to ...

You are being asked to take part in this study because you are experiencing fatigue that is related to your cancer. Cancer related fatigue is a very common symptom in people with cancer. The purpose of this study is to: See if taking the study agent, armodafinil, at a dose ...

To demonstrate the antitumor activity of Antineoplaston A10 and AS2-1 in the treatment of children with primary malignant brain tumors by determining the proportion of patients who experience an objective tumor response. To evaluate the adverse effects and tolerance of Antineoplaston A10 and AS2-1 in these patients. Inclusion Criteria Patients ...

Removing a tumor from a patients brain is hard to do because, very often, brain tumors do not have boundaries that are easy for the patients surgeon to find. In many cases, the surgeon can't tell exactly where the tumor begins or ends. The surgeon usually can remove most of ...

The combination of sorafenib, valproic acid, and sildenafil may have therapeutic potential for the treatment of recurrent high-grade glioma in the clinic. The combination of sorafenib and valproic acid is predicated on the basis that sorafenib activity is enhanced by HDAC inhibition. The addition of sildenafil is based on its ...

This is a phase I/II study of mebendazole in combination with standard of care agents for pediatric patients with gliomas. Patients with low-grade gliomas will receive a regimen of mebendazole in combination with vincristine, carboplatin, and temozolomide. Patients with high-grade gliomas and diffuse intrinsic pontine gliomas will receive a regimen ...

This is a multicenter phase I trial of APX005M in patients with recurrent or refractory primary malignant central nervous system tumor, or newly diagnosed diffuse intrinsic pontine glioma. APX005M is a humanized IgG1 mAb that binds to CD40. APX005M binds to both human and cynomolgus monkey CD40 with high affinity, ...

PAC-1 in combination with temozolomide (Component 2): after the MTD is established for single agent PAC-1 in Component 1, a modified-Fibonacci dose-escalation 3+3 design starts in Component 2, at a PAC-1 dose one level lower than the MTD of PAC-1 established in the single agent PAC-1 component (i.e., Component 1) ...